145 related articles for article (PubMed ID: 23665303)
21. Four monoclonal antibodies against capsular polysaccharides of Neisseria meningitidis serogroups A, C, Y and W135: its application in identity tests.
Reyes F; Amin N; Otero O; Aguilar A; Cuello M; Valdés Y; García LG; Cardoso D; Camacho F
Biologicals; 2013 Jul; 41(4):275-8. PubMed ID: 23791517
[TBL] [Abstract][Full Text] [Related]
22. Saccharide dosage content of meningococcal polysaccharide conjugate vaccines determined using WHO International Standards for serogroup A, C, W, Y and X polysaccharides.
Gao F; Beresford N; Lockyer K; Burkin K; Rigsby P; Bolgiano B
Biologicals; 2021 Apr; 70():53-58. PubMed ID: 33518432
[TBL] [Abstract][Full Text] [Related]
23. Capillary electrophoretic analysis of meningococcal polysaccharide-diphtheria toxoid conjugate vaccines.
Lamb DH; Summa L; Lei QP
Dev Biol (Basel); 2000; 103():251-8. PubMed ID: 11214245
[TBL] [Abstract][Full Text] [Related]
24. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
[TBL] [Abstract][Full Text] [Related]
25. Control and lot release of meningococcal group C conjugate vaccines.
Suker J; Feavers IM; Corbel MJ; Jones C; Bolgiano B
Expert Rev Vaccines; 2004 Oct; 3(5):533-40. PubMed ID: 15485333
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT.
Findlow H; Borrow R
Adv Ther; 2013 May; 30(5):431-58. PubMed ID: 23712402
[TBL] [Abstract][Full Text] [Related]
27. MenACWY-TT vaccine for active immunization against invasive meningococcal disease.
Papaevangelou V; Spyridis N
Expert Rev Vaccines; 2012 May; 11(5):523-37. PubMed ID: 22827239
[TBL] [Abstract][Full Text] [Related]
28. Quantitative proton nuclear magnetic resonance evaluation and total assignment of the capsular polysaccharide Neisseria meningitidis serogroup X.
Garrido R; Puyada A; Fernández A; González M; Ramírez U; Cardoso F; Valdés Y; González D; Fernández V; Vérez V; Vélez H
J Pharm Biomed Anal; 2012 Nov; 70():295-300. PubMed ID: 22877873
[TBL] [Abstract][Full Text] [Related]
29. Meningococcal disease: a review on available vaccines and vaccines in development.
Bröker M; Fantoni S
Minerva Med; 2007 Oct; 98(5):575-89. PubMed ID: 18043565
[TBL] [Abstract][Full Text] [Related]
30. Quantitation of residual sodium dodecyl sulfate in meningococcal polysaccharide by gas chromatography-mass spectrometry.
Shende N; Karale A; Marathe P; Chakraborty S; Mallya AD; Dhere RM
Biologicals; 2019 Jul; 60():68-74. PubMed ID: 31126703
[TBL] [Abstract][Full Text] [Related]
31. New meningococcal C polysaccharide-tetanus toxoid conjugate Physico-chemical and immunological characterization.
Cuello M; Cabrera O; Martinez I; Del Campo JM; Camaraza MA; Sotolongo F; Pérez O; Sierra G
Vaccine; 2007 Feb; 25(10):1798-805. PubMed ID: 17240485
[TBL] [Abstract][Full Text] [Related]
32. Meningococcal vaccines.
Collins CL; Pollard AJ
Curr Opin Investig Drugs; 2002 Jul; 3(7):975-9. PubMed ID: 12186274
[TBL] [Abstract][Full Text] [Related]
33. Meningococcal X polysaccharide quantification by high-performance anion-exchange chromatography using synthetic N-acetylglucosamine-4-phosphate as standard.
Micoli F; Adamo R; Proietti D; Gavini M; Romano MR; MacLennan CA; Costantino P; Berti F
Anal Biochem; 2013 Nov; 442(2):259-61. PubMed ID: 23938776
[TBL] [Abstract][Full Text] [Related]
34. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults.
Southern J; Deane S; Ashton L; Borrow R; Goldblatt D; Andrews N; Balmer P; Morris R; Kroll JS; Miller E
Clin Diagn Lab Immunol; 2004 Nov; 11(6):1100-4. PubMed ID: 15539513
[TBL] [Abstract][Full Text] [Related]
35. Characteristics of two types of meningococcal group C polysaccharide conjugates using tetanus toxoid as carrier protein.
Beuvery EC; Roy R; Kanhai V; Jennings HJ
Dev Biol Stand; 1986; 65():197-204. PubMed ID: 3104115
[TBL] [Abstract][Full Text] [Related]
36. Quadrivalent meningococcal conjugate vaccines.
Pace D; Pollard AJ; Messonier NE
Vaccine; 2009 Jun; 27 Suppl 2():B30-41. PubMed ID: 19477560
[TBL] [Abstract][Full Text] [Related]
37. Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases.
Bardotti A; Averani G; Berti F; Berti S; Carinci V; D'Ascenzi S; Fabbri B; Giannini S; Giannozzi A; Magagnoli C; Proietti D; Norelli F; Rappuoli R; Ricci S; Costantino P
Vaccine; 2008 Apr; 26(18):2284-96. PubMed ID: 18378363
[TBL] [Abstract][Full Text] [Related]
38. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.
Marchant CD; Miller JM; Marshall GS; Blatter M; Aris E; Friedland LR; Boutriau D;
Pediatr Infect Dis J; 2010 Jan; 29(1):48-52. PubMed ID: 20035207
[TBL] [Abstract][Full Text] [Related]
39. Single validation of CE method for determining free polysaccharide content in a Brazilian meningococcal C conjugate vaccine.
Medeiros de Souza I; Neto da Silva M; Figueira ES; Leal Mde L; Jessouroun E; Pereira Abrantes Sde M; Brasileiro da Silveira IA
Electrophoresis; 2013 Dec; 34(22-23):3221-6. PubMed ID: 24037919
[TBL] [Abstract][Full Text] [Related]
40. Bioanalysis of meningococcal vaccines.
Ravenscroft N; Wheeler JX; Jones C
Bioanalysis; 2010 Feb; 2(2):343-61. PubMed ID: 21083312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
